Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/1097-0045(20001001)45:2<184::aid-pros13>3.0.co;2-k | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Microtubule depolymerization induces ferroptosis in neuroblastoma cells.
IUBMB Life
December 2024
Department of Biosciences & Bioengineering, Indian Institute of Technology Bombay, Mumbai, India.
Estramustine (EM), a clinically successful hormone-refractory anti-prostate cancer drug, exhibited potent anti-proliferative activity, depolymerized microtubules, blocked cells at mitosis, and induced cell death in different cancer cells. Altered iron metabolism is a feature of cancer cells. Using EM, we examined the plausible relationship between microtubule depolymerization and induction of ferroptosis in human neuroblastoma (SH-SY5Y and IMR-32) cells.
View Article and Find Full Text PDFComprehensive Review on Recent Strategies for Management of Prostate Cancer: Therapeutic Targets and SAR.
Mini Rev Med Chem
May 2024
Faculty of Pharmaceutical Sciences, Desh Bhagat University, Amloh Road, Mandi Gobindgarh, Punjab, 147301, India.
Prostate cancer is a disease that is affecting a large population worldwide. Androgen deprivation therapy (ADT) has become a foundation for the treatment of advanced prostate cancer, as used in most clinical settings from neo-adjuvant to metastatic stage. In spite of the success of ADT in managing the disease in the majority of men, hormonal manipulation fails eventually.
View Article and Find Full Text PDFDesigned ankyrin repeat proteins for detecting prostate-specific antigen expression .
RSC Chem Biol
July 2023
University of Zurich, Department of Chemistry Winterthurerstrasse 190 CH-8057, Zurich Switzerland https://www.hollandlab.org https://twitter.com/HollandLab_ +41-44-63-53990.
Late-stage prostate cancer often acquires resistance to conventional chemotherapies and transforms into a hormone-refractory, drug-resistant, and non-curative disease. Developing non-invasive tools to detect the biochemical changes that correlate with drug efficacy and reveal the onset of drug resistance would have important ramifications in managing the treatment regimen for individual patients. Here, we report the selection of new Designed Ankyrin Repeat Proteins (DARPins) that show high affinity toward prostate-specific antigen (PSA), a biomarker used in clinical monitoring of prostate cancer.
View Article and Find Full Text PDFPreclinical Characterization of the Lu-Labeled Prostate Stem Cell Antigen (PSCA)-Specific Monoclonal Antibody 7F5.
Int J Mol Sci
May 2023
Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research, 01328 Dresden, Germany.
Prostate specific membrane antigen (PSMA) is an excellent target for imaging and treatment of prostate carcinoma (PCa). Unfortunately, not all PCa cells express PSMA. Therefore, alternative theranostic targets are required.
View Article and Find Full Text PDFDevelopment of heterodimeric estrogen receptor alpha antagonists to target simultaneously the ligand and coactivator binding site.
Arch Pharm (Weinheim)
July 2023
Department of Pharmaceutical Chemistry, Institute of Pharmacy, Center for Molecular Bioscience Innsbruck, Innsbruck, Austria.
One-third of breast cancer patients will develop recurrent cancer within 15 years of endocrine treatment. Notably, tumor growth in a hormone-refractory state still relies on the interaction between estrogen receptor alpha (ERα) and upregulated coactivators. Herein, we suggest that simultaneous targeting of the primary ligand binding site (LBS) and the coactivator binding site (CABS) at ERα represents a promising alternative therapeutic strategy to overcome mutation-driven resistance in breast cancer.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!